T1	p 109 192	patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study (
T2	p 356 385	primary Raynaud 's phenomenon
T3	p 391 403	) in Korea .
T4	p 412 432	RP were screened and
T5	p 740 761	Ninety-three subjects
T6	p 1114 1131	Korean patients .
T7	p 1171 1184	RP patients .
T8	i 44 54	nifedipine
T9	i 78 99	Ginkgo biloba extract
T10	i 256 266	nifedipine
T11	i 287 302	nifedipine SR )
T12	i 317 338	Ginkgo biloba extract
T13	i 342 351	treatment
T14	i 456 477	nifedipine SR group (
T15	i 484 490	N ) or
T16	i 495 524	Ginkgo biloba extract group (
T17	i 1023 1033	nifedipine
T18	i 1061 1082	Ginkgo biloba extract
T19	o 21 54	efficacy and safety of nifedipine
T20	o 233 284	efficacy and safety of nifedipine sustained release
T21	o 391 392	)
T22	o 542 547	ratio
T23	o 673 691	the RP attack rate
T24	o 911 933	serious adverse events
T25	o 949 970	almost adverse events
T26	o 976 980	mild
T27	o 1034 1036	SR